re: AUPH - Aurinia Pharmaceuticals

quote:

---

The rapid onset and overall efficacy (as measured by the STT and FCS) demonstrated by VOS in this head-to-head study conducted against Restasis® is astounding and could be a game changer in the treatment landscape for dry eye," said Joseph Tauber, Principal Investigator of the study.

---

of course it's from financial blog but not seeking alpha at least. I did look up this guy and found this from wize pharma who put him on their scientific advisory board.

quote:

---

Dr. Tauber is an internationally recognized authority in the field of ocular surface diseases, including DES and meibomitis management. He has been a Principal Investigator in dozens of clinical research programs, including those that led to the approval of the only two medications approved by the FDA for the treatment of DES - Restasis® and Xiidra®.

---